Idera Pharmaceuticals Announces Closing of Common Share Offering
CAMBRIDGE, Mass. -- May 07, 2013
Idera Pharmaceuticals (NASDAQ: IDRA) announced today the closing of its
previously announced $16.5 million underwritten public offering of (i)
17,500,000 shares of common stock and related warrants to purchase up to
17,500,000 shares of common stock at an exercise price of $0.47 per share, and
(ii) pre-funded warrants to purchase up to 15,816,327 shares of common stock
at an exercise price of $0.01 per share and related warrants to purchase up to
15,816,327 shares of common stock at an exercise price of $0.47 per share. The
gross proceeds to Idera Pharmaceuticals from this offering were $16.5 million,
before deducting underwriting discounts and commissions and other estimated
offering expenses payable by Idera and excluding the proceeds, if any, from
the exercise of warrants.
Idera anticipates using the net proceeds from the offering to fund a planned
Phase 2 clinical trial of IMO-8400 in patients with psoriasis, and for working
capital and general corporate purposes.
Piper Jaffray & Co. acted as sole manager for the offering.
This offering was made pursuant to a final prospectus relating to the offering
that was filed with the SEC on May 2, 2013. Copies of the final prospectus
relating to the offering may be obtained from the Securities and Exchange
Commission website at http://www.sec.gov, or from the underwriters at Piper
Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03,
Minneapolis, MN 55402, via telephone at 800-747-3924 or email at
This press release shall not constitute an offer to sell or the solicitation
of an offer to buy any of Idera Pharmaceuticals’ securities. No offer,
solicitation or sale of will be made in any jurisdiction in which such offer,
solicitation or sale is unlawful.
Idera Pharmaceuticals, Inc.
Lou Arcudi, 617-679-5517
Press spacebar to pause and continue. Press esc to stop.